Interim Assessement Report The EMA review was started by the Agency’s Committee for Medicinal Products for Human Use (CHMP) to support decision-making by health authorities. This first interim report includes information on seven experimental medicines intended for the treatment of people infected with the Ebola virus: BCX4430 (Biocryst); Brincidofovir (Chimerix); Favipiravir (Fujifilm Corporation/Toyama); TKM-100802 (Tekmira); AVI-7537 (Sarepta); ZMapp (Leafbio Inc.); Anti-Ebola F(ab’)2 (Fab’entech). The amount of information available for the seven treatments is highly variable. For some compounds there is no data from use in human subjects available. A small number of treatments have been administered to patients in the current Ebola outbreak as compassionate use. Finally, there are also medicines included in this review that have already been studied in humans, albeit for the treatment of other viral diseases.